Benzodiazepines & Ibogaine:
An Honest Clinical Guide

Pre-Arrival Assessment (Remote)

Before you fly, our medical director reviews your specific benzodiazepine, daily dose, duration of use, route of acquisition, prior taper attempts, concurrent substances, EKG, and bloodwork. We calculate your total daily dose in diazepam equivalents and design your individualized onsite taper. Critically: you do not taper at home. Self-directed benzo tapering is exactly the scenario that produces withdrawal seizures, and we do not ask any patient to attempt it.

Arrival & Baseline (Days 1-2)

You arrive on your current prescribed dose. Days one and two are dedicated to baseline cardiac monitoring, neurological assessment, hydration, lab confirmation, and orientation. No dose reduction occurs yet. If you are on a short-acting benzodiazepine such as alprazolam or lorazepam, our medical director typically initiates a crossover to an equivalent dose of diazepam to flatten the pharmacokinetic curve and eliminate interdose withdrawal before reduction begins.

Onsite TA Booster Taper (Days 2 onward)

From day two, twice-daily ibogaine TA booster doses begin. The boosters serve two purposes: they pre-load noribogaine plasma levels in preparation for the flood dose, and they address the underlying trauma, anxiety, and concurrent opioid dependence that drove the benzodiazepine use in the first place. Concurrently, your benzodiazepine dose is stepped down under continuous 24/7 physician supervision with telemetry-grade cardiac and neurological monitoring. Step size and pace are calibrated to your specific medication and tolerance — any sign of withdrawal is addressed instantly because clinical staff are with you throughout.

HCl Flood Dose (Protocol Window)

The HCl flood dose is administered when two conditions are met simultaneously: your benzodiazepine has been titrated to the protocol-defined safe threshold, and noribogaine has been pre-loading from the booster phase. Patients with significant benzo history receive flood dosing calibrated to their pharmacological profile, with enhanced cardiovascular monitoring throughout the session. The target is not necessarily zero benzodiazepine — it is the threshold at which the GABA system has stabilized enough to safely tolerate the flood.

Post-Flood Taper Completion & Integration

After the flood dose resolves the primary addiction and processes the underlying trauma, the remaining benzodiazepine taper continues onsite during the integration phase with continued TA booster support. Most patients find this phase markedly easier than any prior outpatient attempt, because the trauma and anxiety drivers have been meaningfully addressed. Our team supports the transition through the full 90-day aftercare period with continued check-ins and clinical support.

Ibogaine does not act on the GABA-A receptor system that benzodiazepines occupy, so it cannot pharmacologically substitute for a benzodiazepine. What our protocol does is manage your benzodiazepine taper onsite, under continuous physician supervision, while twice-daily ibogaine TA booster doses simultaneously address the underlying drivers of your anxiolytic use — typically PTSD, treatment-resistant anxiety, depression, or concurrent opioid dependence. The TA boosters and the eventual flood dose target the trauma and neurochemical dysregulation that originally created the need for the benzodiazepine, while the taper itself is handled with the precision and 24/7 monitoring it requires. Both processes happen at MindScape, not at home.

Yes. You arrive on your current prescribed dose. The taper happens onsite under 24/7 physician supervision with continuous cardiac and neurological monitoring. We do not require — and do not recommend — that you taper at home before arrival, because unsupervised benzodiazepine tapering is exactly the scenario that produces withdrawal seizures. Onsite, we can step the dose down precisely, hold or reverse a step instantly if symptoms emerge, cross over short-acting agents (alprazolam, lorazepam) to diazepam to smooth the pharmacokinetic curve, and use TA booster support to address the underlying anxiety drivers in parallel. Our medical director will give you an honest timeline based on your specific medication, dose, and duration.

Benzodiazepine withdrawal can cause seizures, which can be fatal. This is categorically different from opioid withdrawal, which is extremely uncomfortable but rarely life-threatening. The GABA-A receptor system that benzodiazepines modulate controls neuronal excitability throughout the brain. Abrupt cessation after chronic use produces a state of neural hyperexcitability that can result in generalized tonic-clonic seizures, status epilepticus, delirium, and cardiovascular instability. This is why benzodiazepine tapering must always be physician-supervised and why ibogaine cannot be used as a shortcut to bypass this process.

This is one of the most common presentations we see — the VA frequently prescribes both opioids and benzodiazepines to veterans, and many patients arriving from pain management clinics are on combinations of both. Both medications are managed onsite, in parallel. From day one, twice-daily ibogaine TA boosters begin building noribogaine plasma levels, which addresses the opioid dependency. Concurrently, our medical director steps down the benzodiazepine dose under continuous cardiac and neurological monitoring, with crossover to diazepam if you are on a short-acting agent. The HCl flood dose is timed to a window when both medications are at protocol-defined safe levels. Post-flood, the remaining benzodiazepine taper continues onsite during integration with continued booster support. We have extensive experience with this exact scenario.

This is extremely common. Many patients began using benzodiazepines — whether prescribed or obtained otherwise — because they were the only thing that interrupted the hypervigilance, insomnia, and anxiety produced by unresolved trauma. Ibogaine directly addresses the trauma that drives the self-medication. By resolving the underlying PTSD, anxiety, or depression through neuroplastic reset and deep psychological processing, the need for the benzodiazepine often diminishes naturally. Our integration team works with you to build sustainable alternatives for anxiety management during the neuroplastic window following treatment.

Long-acting benzodiazepines like diazepam (Valium) and clonazepam (Klonopin) are actually easier to taper because their long half-lives produce smoother transitions between doses. The most challenging tapers involve short-acting, high-potency benzodiazepines: alprazolam (Xanax) and lorazepam (Ativan) at high doses or after years of use. These create interdose withdrawal — symptoms between each dose — that makes the taper process more uncomfortable. Our medical director typically crossover-tapers short-acting benzos to an equivalent dose of diazepam before beginning the reduction schedule, which smooths the process considerably.